Expand all sections

Eptacog alfa (activated)

NovoSeven

Extended indication

Extension of indication to include treatment of severe postpartum haemorrhage
Therapeutic value

No estimate possible yet
Registration phase

Registration application pending

Product

Active substance

Eptacog alfa (activated)
Domain

Cardiovascular diseases
Reason of inclusion

Indication extension
Main indication

Other non-oncological hematological medications
Extended indication

Extension of indication to include treatment of severe postpartum haemorrhage
Proprietary name

NovoSeven
Manufacturer

Novo Nordisk
Route of administration

Intravenous
Therapeutical formulation

Injection
Budgetting framework

Intermural (MSZ)

Registration

Registration route

Centralised (EMA)
Submission date

October 2021
Expected Registration

August 2022
Registration phase

Registration application pending

Therapeutic value

Therapeutic value

No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.